Daniel Markwardt
Impact in
- Hepatology top 10%
- Liver Disease and Transplantation
- Hepatocellular Carcinoma Treatment and Prognosis
-
- Acute Kidney Injury Research
- Chronic Kidney Disease and Diabetes
Papers in
-
- Liver Disease and Transplantation 3
- Oncology 3
- PARP inhibition in cancer therapy 1
- Pancreatic and Hepatic Oncology Research 1
- COVID-19 and healthcare impacts 1
- Co-authors
- Alexander L. Gerbes (4 shared papers)Christian J. Steib (3 shared papers)Richard Moreau (1 shared paper)Marco Pavesi (1 shared paper)Elisabet García (1 shared paper)Frederik Nevens (1 shared paper)Flemming Bendtsen (1 shared paper)Daniel Teupser (1 shared paper)
- Journals
- European Journal of Clinical Investigation (1 paper)Digestive and Liver Disease (1 paper)JCO Precision Oncology (1 paper)Hepatology (1 paper)Medical Oncology (1 paper)
- Partner nations
- GermanySwitzerlandBelgium
In The Last Decade
Daniel Markwardt
7 papers receiving 132 citations
Peers
Comparison fields: 5 of 27
- Hepatology 90
- Nephrology 29
- Epidemiology 45
- Pharmacology 11
- Critical Care and Intensive Care Medicine 5
Countries citing papers authored by Daniel Markwardt
This map shows the geographic impact of Daniel Markwardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Markwardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Markwardt more than expected).
Fields of papers citing papers by Daniel Markwardt
This network shows the impact of papers produced by Daniel Markwardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Markwardt. The network helps show where Daniel Markwardt may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel Markwardt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 75 | |
| 2 | 2022 | 24 | |
| 3 | 2020 | 13 | |
| 4 | 2019 | 9 | |
| 5 | 2019 | 8 | |
| 6 | 2022 | 2 | |
| 7 | 2023 | 1 | |
| 8 | 2025 | 0 |
About Daniel Markwardt
Daniel Markwardt is a scholar working on Hepatology, Oncology, Infectious Diseases, Pathology and Forensic Medicine and Emergency Medical Services, having authored 8 papers that have together received 132 indexed citations. Recurring topics across this work include Liver Disease and Transplantation (3 papers), PARP inhibition in cancer therapy (1 paper), COVID-19 Clinical Research Studies (1 paper), Pancreatic and Hepatic Oncology Research (1 paper), Cancer Genomics and Diagnostics (1 paper), Disaster Response and Management (1 paper), COVID-19 and healthcare impacts (1 paper) and Genetic factors in colorectal cancer (1 paper). The work is most often cited by research in Hepatology (90 citations), Nephrology (29 citations), Epidemiology (45 citations), Pharmacology (11 citations) and Critical Care and Intensive Care Medicine (5 citations). Daniel Markwardt has collaborated with scholars based in Germany, Switzerland and Belgium. Frequent co-authors include Alexander L. Gerbes, Christian J. Steib, Richard Moreau, Marco Pavesi, Elisabet García, Frederik Nevens, Flemming Bendtsen, Daniel Teupser, Mauro Bernardi and Vicente Arroyo. Their work appears in journals such as European Journal of Clinical Investigation, Digestive and Liver Disease, JCO Precision Oncology, Hepatology and Medical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.